Advances in therapeutic approaches to gastric cancer. (PubMed, CA Cancer J Clin) - Sep 18, 2026 - "In locally advanced disease, resection of the primary lesion and D2 lymphadenectomy, defined as dissection of lymph nodes along two levels of blood vessels supplying the stomach, remains the cornerstone of curative surgery, whereas perioperative chemotherapy, particularly oxaliplatin-based regimens, has demonstrated improved survival benefits compared with surgery alone...Targeted agents include claudin 18.2 antibody, with zolbetuximab establishing a new first-line standard for claudin 18.2-positive disease, and antibody-drug conjugates, such as trastuzumab deruxtecan for human epidermal growth factor receptor 2-positive disease, both of which have revolutionized treatment paradigms. Emerging strategies include dual immune checkpoint inhibition, bispecific antibodies, chimeric antigen receptor T-cell therapy, and fibroblast growth factor receptor 2b-targeting agents. Ultimately, the field is moving toward personalized, biomarker-driven approaches within..."
IO biomarker • Journal • Review • Gastric Cancer • Microsatellite Instability • Oncology • Palliative care • Solid Tumor • CLDN18 • FGFR2 • HER-2 • MSI • PD-L1
|
|
Feng Wang; Jia-Fu Ji; Rui-Hua Xu; Shu-Qiang Yuan; Xiu-Juan Qu; Ye He; Yi Ba; Yu-Jing Zhang; Yuan-Fang Li; Zi-Xian Wang
|